These bearish "reports" are often poorly written junk, but infortunately they resonate and find an audience due to real and notable missteps by Missling. He misrepresents trial endpoint results, designs small trials, changes endpoints with poor disclosure, announces expected trials that remain un-started for years, doesn't explore recent "successful" trial results and next steps, and awards himself shares for ordinary operational milestones. At this point Rett, PD, FX, schizo, etc are clinically dead and all is riding on AD. This is not a confidently, well-run biotech.
The good news is that we have a decent chance of EMA approval for AD in Europe, if our data is as Missling has publicly represented it. I'm counting on Jin et al having been through it and validating it as robust enough for viable submission. (Paper peer reviews don't thoroughly do that, unfortunately.)
Missling's always been a promoter, not a biotech manager. He opens the company up to lawsuits and criticism. Our main drug is better than him.
Market Data 
Markets 
AI
